Talphera (TLPH) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Talphera (TLPH) has outperformed Xilio Therapeutics (XLO) over the past year, losing 15.0% versus a loss of 22.9%. Xilio Therapeutics is the larger company by market cap ($59.6 million vs $56.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLPH | XLO |
|---|---|---|
| Share price | $1.08 | $9.05 |
| Market cap | $56.06M | $59.55M |
| 1-day change | 0.00% | +0.44% |
| YTD return | -5.26% | +1.00% |
| 1-year return | -14.96% | -22.86% |
| 5-year return | -94.71% | — |
| EPS (TTM) | $-0.26 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.57 | $12.59 |
| 52-week low | $0.69 | $6.47 |
| Distance from 52-week high | -31.21% | -28.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +189.81% | +120.99% |
| Average volume | 220.10K | 18.86K |
| Shares outstanding | 51.91M | 6.58M |
| Employees | 12 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
TLPH vs XLO FAQ
Which is bigger, Talphera or Xilio Therapeutics?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $59.55M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, TLPH or XLO?
TLPH returned -14.96% over the past 12 months, compared with -22.86% for XLO (price return, excluding dividends). Past performance does not predict future results.
Are Talphera and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.